TechnipFMC (FTI) Seals EPCI Deal for Jubilee South East Project
Zacks Investment Research | Jul 12, 2021 04:09AM ET
TechnipFMC plc FTI recently secured a major contract from Tullow Ghana Limited for integrated engineering, procurement, construction and installation (iEPCI) on the Jubilee South East development, located off the coast of Ghana. Jubilee South East is an extension of the Jubilee field. The contract is worth a value between $75 million and $250 million.
The agreement will be TechnipFMC’s first iEPCI project with Tullow Ghana, which will include the delivery and offshore installation of all key subsea equipment comprising manifolds and related controls, flexible risers and flowlines, umbilicals, and subsea structures.
Jonathan Landes, the company’s president in charge of subsea, stated that, “We are proud to continue supporting Tullow Ghana in the development of the Jubilee field. This is the first time Tullow has used our iEPCI™ model, which enables us to collaborate even more closely and simplify project delivery. We will continue to use our Subsea Studio digital solution to optimize the development, execution, and operation of Jubilee South East.”
With the construction of a number of subsea structures including production and water injection manifolds carried out in Ghana, TechnipFMC views this project as a chance to expand its local content.
Last month, TechnipFMC clinched a major EPCI contract from Equinor EQNR on the Kristin Sør field in North Sea. The company will deliver rigid pipes, static and dynamic umbilicals plus pipeline and marine installation of the subsea production facilities, depending on the conditions of the pact.
Apart from the above contract wins, the company gained a significant subsea contract from oil major Petrobras S.A. .
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Get The News You Want
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.